Diagnostic services provider Genoptix Inc. said Friday that it licensed cancer diagnostic technology from HistoRx Inc.
The companies did not disclose financial terms of the multiyear deal. Genoptix said it will gain exclusive U.S. rights to HistoRx's AQUA technology, which is used to evaluate solid tumors. The Carlsbad, Calif., company also acquired the right to develop and perform three tests for biomarkers in patients with some types of solid tumors.
Shares of Genoptix fell 27 cents to close at $32.53.
Source : http://www.businessweek.com/ap/financialnews/D9DVI9TO0.htm
The companies did not disclose financial terms of the multiyear deal. Genoptix said it will gain exclusive U.S. rights to HistoRx's AQUA technology, which is used to evaluate solid tumors. The Carlsbad, Calif., company also acquired the right to develop and perform three tests for biomarkers in patients with some types of solid tumors.
Shares of Genoptix fell 27 cents to close at $32.53.
Source : http://www.businessweek.com/ap/financialnews/D9DVI9TO0.htm
No comments:
Post a Comment